Pharma Insights

DM is temporary but BD is permanent 😆

Happy Guru Purnima 🙏🌻

औषधि फिर्ता (Recall) गर्ने सम्बन्धी अत्यन्त जरुरी सूचना।(२०८३/०४/१२)

J&J offers $5.5bn settlement in lawsuits claiming talc link to cancer
Johnson & Johnson offers $5.5bn to settle talc cancer lawsuits.
Settlement resolves thousands of US lawsuits, with a record UK case against the company under way.
Johnson & Johnson (J&J) has agreed to pay $5.5bn to settle tens of thousands of lawsuits in the United States that allege its discontinued talc-based baby powder caused ovarian cancer.

The pharmaceutical giant made the announcement on Monday, saying it covers about 69,000 cases in US federal and state courts, accounting for 99.75 percent of outstanding talc-related cases in the country.
The settlement will only be final once it is accepted by 95 percent of the claimants in state or federal courts.

Talc is a soft mineral and was once a staple ingredient in cosmetics and baby products, but its use has declined as concerns rose over its links to cancer.

In 2024, the World Health Organization classified talc as “probably carcinogenic to humans”.

J&J maintains that there is no evidence that talc causes cancer, but it stopped selling talc-based baby powder in the US in 2020 and worldwide in 2023.

In 2016, a US jury ordered J&J to pay $72m to the family of a woman who died of ovarian cancer, the first such case related to the use of the mineral in the country.

Though the case was overturned a year later, claims against the company have multiplied since, with juries across the US awarding the plaintiffs.

Erik Haas, J&J’s litigation head, said the agreement lets J&J “put this matter behind it”.

Lawyers representing the plaintiffs welcomed the settlement as a good resolution to a decade-long court battle.

The deal does not cover the United Kingdom, where the largest product liability case in UK history – covering more than 7,000 potential claimants – is being adjudicated.
Filed in October 2025, the UK case alleges that J&J knew that its talc could cause cancers, chiefly ovarian and mesothelioma, but continued to sell the product, a claim the company also denies.
Source: https://aje.news/eu8p9o

Congratulations to Manoj Kumar Sah 👏💙
A remarkable achievement that every pharmacy student can be proud of.
Manoj Kumar Sah, a B.Pharm student from Chitwan Medical College, Nepal, while studying the 14th edition of Goodman & Gilman's The Pharmacological Basis of Therapeutics—one of the world's most respected pharmacology textbooks—Manoj Kumar Sah identified an editorial error in the explanation of bioavailability (F).
Instead of keeping it to himself, he professionally contacted the book's authors, Professor Laurence Brunton and Professor Björn Knollmann, explaining the issue with clear scientific reasoning.
The response was extraordinary.
Professor Laurence Brunton acknowledged that the observation was correct, confirmed it was an editorial error, and stated that the mistake would be corrected in the online version and the next published edition of the textbook.
This is a powerful reminder that science grows through curiosity, careful reading, and the courage to ask questions.
Your achievement has made the global pharmacy community a little better.
Heartiest congratulations, Manoj Kumar Sah!
Keep inspiring students to read critically, think scientifically, and contribute to the advancement of pharmaceutical education.
Great discoveries don't always come from laboratories—sometimes they begin with a student who dares to question a textbook.

Pharmacist's advice:

In a world full of tachycardia be someone's beta blocker.

औषधि व्यवस्था विभागले सोमबार सूचना निकालेर नयाँ फार्मेसी दर्ता तथा सञ्चालनमा रहेका फार्मेसी नवीकरणका लागि स्थानीय तहको सिफारिस पत्र अनिवार्य चाहिने व्यवस्था गरिएको बताएको छ।